Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 877 across all filing types
Latest filing 2014-10-10 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical får CE-märkning av ytterligare en produkt för individanpassad behandling av skadade knäleder, Episealer® Trochlea
Regulatory Filings Classification · 95% confidence The document is a press release dated October 10, 2014, announcing that Episurf Medical has received CE-marking for a new product, Episealer® Trochlea. It discusses the ability to start marketing and sales in Europe and the initiation of a controlled product launch (CPL). This type of announcement, detailing a specific operational or regulatory milestone (like CE marking) that enables commercial activity, is typically classified as a general regulatory announcement or a specific operational update. Since it is not a formal financial report (10-K, IR, ER, MRQ), a management change (MANG), or a director's dealing (DIRS), and it is a specific, non-financial operational update, it fits best under the general 'Regulatory Filings' (RNS) category as a regulatory milestone announcement, or potentially a Capital/Financing Update (CAP) if it were related to fundraising, which it is not. Given the context of a press release announcing a regulatory approval (CE-marking) that allows market entry, RNS is the most appropriate general regulatory fallback category for such specific, non-standard announcements.
2014-10-10 Swedish
Ytterligare en klinik ansluten till Episurf Medicals pågående kliniska prövning
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 30, 2014, written in Swedish. The content discusses an update regarding a clinical trial ('kliniska prövning') for a medical product (Episealer® Femoral Condyle) and the addition of a new hospital to the trial. It details patient recruitment, study goals (safety and performance evaluation), and future plans (scientific publications, US study). This type of announcement, detailing operational progress, clinical updates, or minor corporate news that doesn't fit a specific financial report category (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing or Announcement. Since it is not a formal financial report, a management discussion, or a specific legal/insider trade filing, the most appropriate fallback category is Regulatory Filings (RNS). The document length (3304 chars) is short, but it is providing substantive news rather than just announcing the publication of a larger report, thus RNS is preferred over RPA.
2014-09-30 Swedish
Episurf Medical rekryterar sälj- och marknadschef för direktmarknadssatsning i Benelux
Board/Management Information Classification · 98% confidence The document is a press release dated September 1, 2014, announcing the recruitment of a Sales and Marketing Manager for the Benelux region. This announcement details a change in senior personnel (a key hire for a strategic market expansion). According to the definitions, the 'Board/Management Information (Code: MANG)' category covers the 'Announcement of changes in the company's board of directors or senior management.' This fits the content perfectly, as it announces a key management hire (Sälj- och marknadschef/Sales and Marketing Manager). It is not an earnings release, a full report, or a dividend notice.
2014-09-01 Swedish
Sportsmedicine Umeå ansluter sig till Episurf Medicals pågående kliniska prövning
Legal Proceedings Report Classification · 99% confidence The document is a press release dated August 22, 2014, announcing that a specialist clinic (Sportsmedicine Umeå) is joining an ongoing clinical trial for the company's product (Episealer® Femoral Condyle). It discusses the expansion of patient recruitment for a clinical study and mentions future plans for scientific publications and US market approval studies. This content relates to ongoing research, product development, and clinical progress, which is typically communicated via general regulatory announcements or investor relations updates, rather than a formal financial report (like 10-K or IR) or a specific management/board change. Since it is a general announcement that doesn't fit the highly specific categories like M&A (TAR), Director's Dealing (DIRS), or Earnings Release (ER), the most appropriate fallback category is Regulatory Filings (RNS), as it is a standard corporate announcement to the market.
2014-08-22 Swedish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Episurf Medical AB for the period of January 1 to June 30, 2014. It contains comprehensive financial statements, management commentary, key performance indicators, and operational updates for the second quarter and the first half of the year. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. H2 2014
2014-08-22 Swedish
Episurf Medical rekryterar Global sales and marketing director samt Sales director EMEA
Board/Management Information Classification · 98% confidence The document is a press release dated July 10, 2014, announcing the recruitment of a Global Sales and Marketing Director and a Sales Director EMEA for Episurf Medical. The content focuses entirely on changes in senior management and key personnel appointments within the company's commercial structure. This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2014-07-10 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.